HIGHLIGHTS
- who: Ard van Veelen from the (1) Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, POBOX , AZ, Maastricht, the Netherlands have published the research: Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: the OSIBOOST trial, in the Journal: (JOURNAL)
- what: In this study, the boosting capacity of cobicistat on osimertinib exposure was evaluated in patients with NSCLC who had a low osimertinib plasma trough concentration, i.e. ≤195 ng/mL. 15 Future research could therefore also focus on evaluating whether the approach presented in this study could . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.